The DOI matches its Crossref record; 276 of the 278 references it cites were found in a registry or an index; 6 of the 225 sources its claims cite were checked for support.
Hepatokines and metabolism: Deciphering communication from the liver
Open accessAbstract
BACKGROUND: The liver is a key regulator of systemic energy homeostasis and can sense and respond to nutrient excess and deficiency through crosstalk with multiple tissues. Regulation of systemic energy homeostasis by the liver is mediated in part through regulation of glucose and lipid metabolism. Dysregulation of either process may result in metabolic dysfunction and contribute to the development of insulin resistance or fatty liver disease. SCOPE OF REVIEW: The liver has recently been recognized as an endocrine organ that secretes hepatokines, which are liver-derived factors that can signal to and communicate with distant tissues. Dysregulation of liver-centered inter-organ pathways may contribute to improper regulation of energy homeostasis and ultimately metabolic dysfunction. Deciphering the mechanisms that regulate hepatokine expression and communication with distant tissues is essential for understanding inter-organ communication and for the development of therapeutic strategies to treat metabolic dysfunction. MAJOR CONCLUSIONS: In this review, we discuss liver-centric regulation of energy homeostasis through hepatokine secretion. We highlight key hepatokines and their roles in metabolic control, examine the molecular mechanisms of each hepatokine, and discuss their potential as therapeutic targets for metabolic disease. We also discuss important areas of future studies that may contribute to understanding hepatokine signaling under healthy and pathophysiological conditions.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This review describes the liver as an endocrine organ that secretes hepatokines to regulate systemic energy, glucose, and lipid homeostasis. It summarizes key hepatokines, their target tissues and metabolic roles, and discusses their therapeutic potential and unresolved questions in metabolic disease.
Key findings
- The review classifies hepatokines by metabolic impact: beneficial hepatokines include activin-E, ANGPTL4, ANGPTL6, FGF21, GDF15, IGF-1, LCN13, SMOC1, and TSK; detrimental hepatokines include ANGPTL3, ANGPTL8, fetuin-A, hepassocin, LECT-2, and selenoprotein-P.
- Table 1 reports human serum concentration changes in insulin resistance: increased for activin-E, ANGPTL3, ANGPTL6, fetuin-A, FGF21, follistatin, GDF15, hepassocin, LECT2, selenoprotein-P, and Tsukushi; decreased for IGF1, LCN13, and SMOC1; debated for ANGPTL4 and ANGPTL8.
- Several mechanisms are highlighted, including FGF21 signaling through FGFR1c/β-klotho, GDF15 signaling through GFRAL/RET, and ANGPTL3/ANGPTL8 complex inhibition of lipoprotein lipase.
- The review notes that elevated levels of some hepatokines in obesity and diabetes may reflect endocrine resistance, similar to insulin or leptin resistance, and that hepatokines are promising but incompletely validated therapeutic targets.
Methods
- Narrative review; no primary experiments, systematic search strategy, or meta-analysis are described.
- The paper synthesizes published rodent and human literature, including genetic, pharmacological, and clinical trial findings, and presents a summary table of hepatokines with target organs, metabolic roles, and human serum concentration changes in insulin resistance.
- Main analysis is qualitative: mechanisms, target tissues, physiological contexts, and therapeutic implications are discussed for each selected hepatokine.
Limitations
- Stated: the review is “not meant to be an exhaustive list”; future studies are needed to determine how hepatokines integrate with other organokines, how preclinical evidence translates to humans, how hepatokines contribute to disease progression, and how each hepatokine is regulated and acts under healthy and pathophysiological conditions.
- Stated/evident: conflicting findings exist for some hepatokines, such as debated circulating ANGPTL4 and ANGPTL8 levels in metabolic disease and non-reproduced TSK knockout results in a subsequent study.
- Evident: as a narrative review, it lacks systematic search, quantitative synthesis, and primary data to establish causality or effect sizes.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
132 Not checked yet · 15 Own interpretation · 14 No basis given · 3 Partly supported · 1 Own result · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“both mRNA and plasma levels of LCN13 are low in mice with genetic or high-fat diet-induced obesity [254,257].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Supportedcites [254] Zhou, 2013, Lipocalin 13 regulation of glucose and lipid metabolism in obesity, Vitamins & Hormones source
Section III (page not provided) reports extremely low circulating LCN13 in mice with either genetic (db/db) or high-fat-diet-induced obesity. It also reports lower liver LCN13 expression in obese mice than in lean mice, supporting the claim about reduced mRNA expression, though it does not use the term “mRNA” in this passage. (LLM, conf=0.88)
- Partly supportedcites [257] Ekim Üstünel, 2016, Control of diabetic hyperglycaemia and insulin resistance through TSC22D4, Nature Communications sourceExperimental — accuracy not yet measured
In Results (‘LCN13 partially mediates the effects of hepatic TSC22D4’; page unavailable), the paper reports reduced Lcn13 mRNA under high-fat-diet conditions after hepatic TSC22D4 overexpression. It also reports increased serum LCN13 after TSC22D4 deficiency. Neither result establishes that both mRNA and plasma LCN13 are low in untreated mice with genetic or high-fat-diet-induced obesity. (LLM, conf=0.78)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Plasma levels of TSK have been linked to NAFLD and NASH pathologies [269,270].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Partly supportedcites [269] Mouchiroud, 2019, The hepatokine Tsukushi is released in response to NAFLD and impacts cholesterol homeostasis, JCI Insight sourceExperimental — accuracy not yet measured
The Results report elevated circulating TSK in mice with diet-induced steatosis, supporting a link with NAFLD. The Discussion says circulating TSK was below detection in the human samples with elevated liver triglycerides; the measured human plasma elevations were in acetaminophen-induced acute liver failure. These passages do not establish a link between plasma TSK levels and NASH. (LLM, conf=0.88)
- Partly supportedcites [270] Xiong, 2019, Mapping the molecular signatures of diet-induced NASH and its regulation by the hepatokine Tsukushi, Mol Metab sourceExperimental — accuracy not yet measured
The Results section (‘NASH pathogenesis is linked to marked elevation of the hepatokine TSK in plasma’; page unavailable) reports elevated plasma TSK and a correlation with liver-injury markers in mouse NASH models. The Introduction identifies NASH as part of the NAFLD spectrum, but the paper does not separately establish a plasma-TSK link across NAFLD pathologies more broadly. (LLM, conf=0.82)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“Pharmacological administration of FGF21 decreases plasma glucose and lipid levels, improves insulin and leptin sensitivity, decreases hepatic steatosis, increases energy expenditure [[131], [132], [133], [134], [135], [136]], and decreases sugar and alcohol intake in mice [[137], [138], [139], [140], [141], [142]].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [131] Coskun, 2008, Fibroblast growth factor 21 corrects obesity in mice, Endocrinology source
- Not checked yetcites [132] Xu, 2009, Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects, American Journal of Physiology. Endocrinology and Metabolism source
- Not checked yetcites [133] Xu, 2009, Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice, Diabetes source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Pharmacological administration of FGF21 decreases plasma glucose and lipid levels, improves insulin and leptin sensitivity, decreases hepatic steatosis, increases energy expenditure [[131], [132], [133], [134], [135], [136]], and decreases sugar and alcohol intake in mice [[137], [138], [139], [140], [141], [142]].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [137] von Holstein-Rathlou, 2016, FGF21 mediates endocrine control of simple sugar intake and sweet taste preference by the liver, Cell Metabolism source
- Not checked yetcites [138] Talukdar, 2016, FGF21 regulates sweet and alcohol preference, Cell Metabolism source
- Not checked yetcites [139] Tanaka, 2013, Genome-wide meta-analysis of observational studies shows common genetic variants associated with macronutrient intake, American Journal of Clinical Nutrition source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“While adipose tissues and pancreas are well known for their endocrine function, the liver has more recently been identified to contribute to the endocrine control of metabolism by producing liver-derived factors or hepatokines [[7], [8], [9], [10], [11], [12], [13]].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction
What the sources say
- Not checked yetcites [7], [8], [9], [10], [11], [12], [13]
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“FGF21 signals to a receptor complex comprised of FGF receptor 1c (FGFR1c) and its co-receptor β-klotho (KLB) [[143], [144], [145], [146]].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [143] Kurosu, 2007, Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21, Journal of Biological Chemistry source
- Not checked yetcites [144] Suzuki, 2008, betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c, Molecular Endocrinology source
- Not checked yetcites [145] Adams, 2012, The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue, Mol Metab source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Pharmacological administration of FGF21 decreases plasma glucose and lipid levels, improves insulin and leptin sensitivity, decreases hepatic steatosis, increases energy expenditure [[131], [132], [133], [134], [135], [136]], and decreases sugar and alcohol intake in mice [[137], [138], [139], [140], [141], [142]].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [131] Coskun, 2008, Fibroblast growth factor 21 corrects obesity in mice, Endocrinology source
- Not checked yetcites [132] Xu, 2009, Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects, American Journal of Physiology. Endocrinology and Metabolism source
- Not checked yetcites [133] Xu, 2009, Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice, Diabetes source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, obesity may reflect an activin-E resistant state (Figure 3).”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Supporting a potential role for activin-E in human diseases, activin-E levels in humans are increased in individuals with obesity and insulin resistance [31].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [31] Sugiyama, 2018, Inhibin βE (INHBE) is a possible insulin resistance-associated hepatokine identified by comprehensive gene expression analysis in human liver biopsy samples, PloS One source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“and was recently identified as an important regulator of energy expenditure and insulin sensitivity in rodents [30]”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [30] Hashimoto, 2018, Activin E controls energy homeostasis in both Brown and white adipose tissues as a hepatokine, Cell Reports source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 78
- Probably not a substantial claim. 33
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Leukocyte cell-derived chemotaxin 2 (LECT2) is an energy-sensing hepatokine that is positively associated with hepatic inflammatory signaling, obesity, NAFLD, and insulin resistance [239,240].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Partly supportedcites [239] Lan, 2014, LECT2 functions as a hepatokine that links obesity to skeletal muscle insulin resistance, Diabetes sourceExperimental — accuracy not yet measured
The Abstract (p. 3) identifies LECT2 as an energy-sensing hepatokine and reports positive correlations with obesity and insulin resistance in humans. The paper does not establish a positive association with NAFLD: it reports mild steatosis alongside increased liver Lect2 expression in high-fat-fed mice (p. 17). Nor does it establish a positive association with hepatic inflammatory signaling; the Discussion (p. 26) instead describes context-dependent inflammatory effects, including attenuation of liver inflammation. (LLM, conf=0.88)
- Partly supportedcites [240] Jung, 2016, Implication of hepatokines in metabolic disorders and cardiovascular diseases, BBA Clin sourceExperimental — accuracy not yet measured
The LECT2 section (page unavailable) calls LECT2 an energy-sensing hepatokine and reports positive relationships with BMI and insulin resistance, plus elevated levels in obesity and fatty liver. It does not establish a positive association specifically with hepatic inflammatory signaling: the reported induction of proinflammatory cytokines is in human endothelial cells, while involvement in hepatitis is hedged as a possibility. (LLM, conf=0.85)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The liver can sense and respond to nutrient overabundance and deficit by secreting hepatokines, which signal energy status and help regulate nutrient availability to multiple peripheral tissues and the central nervous system (CNS).”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In response to fasting, however, the liver increases hepatic glucose production via glycogenolysis and gluconeogenesis to supply glucose as a fuel source for non-hepatic tissues including the brain and skeletal muscle [15,16].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [15] Roden, 2003, Hepatic glucose metabolism in humans—its role in health and disease, Best Practice & Research Clinical Endocrinology & Metabolism source
- Not checked yetcites [16] Leone, 1999, A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders, Proceedings of the National Academy of Sciences of the U S A source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“NAFLD is the most common chronic liver disease worldwide and a risk factor for type 2 diabetes, obesity, and cardiovascular disease (CVD) [8,12,22].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [8] Iroz, 2015, Hepatokines: unlocking the multi-organ network in metabolic diseases, Diabetologia source
- Not checked yetcites [12] Stefan, 2013, The role of hepatokines in metabolism, Nature Reviews Endocrinology source
- Not checked yetcites [22] Morrison, 2019, Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: a meta-analysis with bias analysis, Liver International source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“ANGPTL3 is exclusively expressed and secreted by the liver and has emerged as an important regulator of plasma triglyceride levels due to its inhibition of LPL in oxidative tissues [34] (Figure 3).”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [34] Conklin, 1999, Identification of a mammalian angiopoietin-related protein expressed specifically in liver, Genomics source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Activin-E expression increases during fasting and is markedly suppressed by loss of the insulin receptor in the liver [10], suggesting dynamic regulation.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [10] Smati, 2020, Regulation of hepatokine gene expression in response to fasting and feeding: influence of PPAR-alpha and insulin-dependent signalling in hepatocytes, Diabetes & Metabolism source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Furthermore, circulating levels of activin-E are elevated in high-fat diet-fed mice and are thought to contribute to resistance to body weight gain [28,30].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [28] Chabicovsky, 2003, Overexpression of activin beta(C) or activin beta(E) in the mouse liver inhibits regenerative deoxyribonucleic acid synthesis of hepatic cells, Endocrinology source
- Not checked yetcites [30] Hashimoto, 2018, Activin E controls energy homeostasis in both Brown and white adipose tissues as a hepatokine, Cell Reports source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Insulin resistance occurs when insulin is unable to properly (1) stimulate glucose uptake into metabolic tissues (skeletal muscle and adipose tissues), (2) suppress hepatic glucose production, and/or (3) reduce adipose tissue lipolysis [17].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [17] Hotamisligil, 2006, Inflammation and metabolic disorders, Nature source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Dysregulation of liver-centered inter-organ pathways may contribute to improper regulation of energy homeostasis and ultimately metabolic dysfunction.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Abstract > Scope of review
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
In the paper
“During hepatic insulin resistance, excess storage of ectopic fat in the liver can contribute to the development of non-alcoholic fatty liver disease (NAFLD) [[17], [18], [19], [20]].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [17], [18], [19], [20]
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The liver regulates systemic glucose homeostasis through hepatic glucose production and glycogen storage.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The liver has recently been recognized as an endocrine organ that secretes hepatokines, which are liver-derived factors that can signal to and communicate with distant tissues.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Abstract > Scope of review
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“FGF21, unlike traditional FGFs, is an endocrine hormone produced and secreted predominantly by the liver [129,130].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [129] Nishimura, 2000, Identification of a novel FGF, FGF-21, preferentially expressed in the liver, Biochimica et Biophysica Acta source
- Not checked yetcites [130] Fon Tacer, 2010, Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse, Molecular Endocrinology source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“FST acts as a multi-faceted hepatokine that is involved in reproduction [181], muscle growth [182], cancer development [183], and metabolism [184].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [181] de Kretser, 2002, Inhibins, activins and follistatin in reproduction, Human Reproduction Update source
- Not checked yetcites [182] Rodino-Klapac, 2009, Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease, Muscle & Nerve source
- Not checked yetcites [183] Shi, 2016, Clinical and therapeutic implications of follistatin in solid tumours, CANCER GENOMICS and PROTEOMICS source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Most of FST's effects on reproductive health and cancer development are related to its interactions with activins and follicle-stimulating hormone, while its effects on muscle growth result from interactions with myostatin [186].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [186] Brown, 2011, Follistatin and follistatin like-3 differentially regulate adiposity and glucose homeostasis, Obesity source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Under fasted conditions, FGF21 increases hepatic gluconeogenesis, β-oxidation, and ketogenesis in mice [142,154].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [142] Hotta, 2009, Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver, Endocrinology source
- Not checked yetcites [154] Potthoff, 2009, FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response, Proceedings of the National Academy of Sciences of the U S A source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“FGF21 signaling to the ventromedial hypothalamus (VMH) is required for its effects on lowering carbohydrate intake but not non-nutritive sweet-taste preference or body weight.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [173] Jensen-Cody, 2020, FGF21 signals to glutamatergic neurons in the ventromedial hypothalamus to suppress carbohydrate intake, Cell Metabolism source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“FGF21 expression is regulated by nutrient signals and subsequently functions to regulate nutrient homeostasis.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Administration of FGF21 analogs to obese and type 2 diabetic subjects improves dyslipidemia, decreases body weight, improves fasting insulin levels, and was recently thoroughly reviewed [136] (Figure 2).”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [136] Gaich, 2013, The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes, Cell Metabolism source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“This robust increase in FGF21 results in increased energy expenditure and lower body weight gain [155,156,160,163] (Figure 2)”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [155] Laeger, 2014, FGF21 is an endocrine signal of protein restriction, Journal of Clinical Investigation source
- Not checked yetcites [156] Maida, 2016, A liver stress-endocrine nexus promotes metabolic integrity during dietary protein dilution, Journal of Clinical Investigation source
- Not checked yetcites [160] Pérez-Martí, 2017, A low-protein diet induces body weight loss and browning of subcutaneous white adipose tissue through enhanced expression of hepatic fibroblast growth factor 21 (FGF21), Molecular Nutrition & Food Research source
- Not checked yetcites [163] Flippo, 2020, FGF21 signaling in glutamatergic neurons is required for weight loss associated with dietary protein dilution, Scientific Reports source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“while it signals the CNS to increase energy expenditure and decrease body weight [169,171,172] (Figure 2).”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [169] BonDurant, 2017, FGF21 regulates metabolism through adipose-dependent and -independent mechanisms, Cell Metabolism source
- Not checked yetcites [171] Ameka, 2019, Liver derived FGF21 maintains core body temperature during acute cold exposure, Scientific Reports source
- Not checked yetcites [172] Owen, 2014, FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss, Cell Metabolism source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In humans, circulating FGF21 levels also increase with obesity [[174], [175], [176]], type 2 diabetes [[176], [177], [178]], and NAFLD [179,180]”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [174] Zhang, 2008, Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans, Diabetes source
- Not checked yetcites [175] Berti, 2015, Fibroblast growth factor 21 is elevated in metabolically unhealthy obesity and affects lipid deposition, adipogenesis, and adipokine secretion of human abdominal subcutaneous adipocytes, Mol Metab source
- Not checked yetcites [176] Mraz, 2009, Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity, Clinical Endocrinology source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Classically recognized as a fasting hormone regulated by the nuclear receptor peroxisome proliferator-activated receptor α (PPARα) [150,151]”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [150] Badman, 2007, Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states, Cell Metabolism source
- Not checked yetcites [151] Inagaki, 2007, Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21, Cell Metabolism source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“FST acts as an inhibitor of members of the TGF-β superfamily, including myostatin and activins [185,186], and can function as a promoter of skeletal muscle growth [187].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [185] Sidis, 2006, Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins, Endocrinology source
- Not checked yetcites [186] Brown, 2011, Follistatin and follistatin like-3 differentially regulate adiposity and glucose homeostasis, Obesity source
- Not checked yetcites [187] Lee, 2010, Regulation of muscle mass by follistatin and activins, Molecular Endocrinology source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“FST is secreted by a broad range of cell types, and plasma levels are thought to result from paracrine/autocrine signaling spillover [188].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [188] Hansen, 2016, Circulating follistatin in relation to energy metabolism, Molecular and Cellular Endocrinology source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Administration of hGDF15 to GFRAL-deficient mice had no effect on body weight, energy expenditure, serum leptin and insulin levels, and food intake compared to wild-type mice given hGDF15 [213].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [213] Yang, 2017, GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand, Natura Med source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Patients with type 2 diabetes have slightly elevated levels of circulating FST and plasma levels associated with glycemic parameters in these patients [188,191,192] (Table 1).”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [188] Hansen, 2016, Circulating follistatin in relation to energy metabolism, Molecular and Cellular Endocrinology source
- Not checked yetcites [191] Hansen, 2013, Plasma follistatin is elevated in patients with type 2 diabetes: relationship to hyperglycemia, hyperinsulinemia, and systemic low-grade inflammation, Diabetes Metab Res Rev source
- Not checked yetcites [192] Hansen, 2016, Exercise-induced secretion of FGF21 and follistatin are blocked by pancreatic clamp and impaired in type 2 diabetes, Journal of Clinical Endocrinology & Metabolism source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Hepassocin has mitogenic activity on hepatocytes, serving as a regulator of hepatic growth and proliferation [218].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [218] Gao, 2014, Hepassocin activates the EGFR/ERK cascade and induces proliferation of L02 cells through the Src-dependent pathway, Cellular Signalling source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“FST functions to increase the phosphorylation of MAPK/ERK1/2 proteins in WAT and increase the expression of Myf5 protein in BAT, which increases UCP1 expression in both tissues [198].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [198] Singh, 2017, Follistatin targets distinct pathways to promote Brown adipocyte characteristics in Brown and white adipose tissues, Endocrinology source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“GDF15 binds with high affinity to GFRAL and its co-receptor RET, which induces phosphorylation of RET, leading to downstream signaling through the AKT, ERK1/2, and phospholipase C (PLCγ) pathways [201,213,215].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [201] Mullican, 2018, Uniting GDF15 and GFRAL: therapeutic opportunities in obesity and beyond, Trends in Endocrinology and Metabolism source
- Not checked yetcites [213] Yang, 2017, GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand, Natura Med source
- Not checked yetcites [215] Hsu, 2017, Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15, Nature source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This discrepancy may have been due to differences in the mode and duration of elevated GDF15 levels.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Plasma levels of hepassocin are associated with fasted plasma glucose, HOMA-IR, and prediabetes and increase in patients with type 2 diabetes (Table 1) [217,220].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“FST is present in three main isoforms, FST288, FST303, and FST315, with FST315 being the predominant isoform found in the circulation [185,194,195].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [185] Sidis, 2006, Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins, Endocrinology source
- Not checked yetcites [194] Shimasaki, 1988, Primary structure of the human follistatin precursor and its genomic organization, Proceedings of the National Academy of Sciences of the U S A source
- Not checked yetcites [195] Schneyer, 2004, Differential distribution of follistatin isoforms: application of a new FS315-specific immunoassay, Journal of Clinical Endocrinology & Metabolism source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The expression of human GDF15 (hGDF15) improved glucose tolerance and insulin sensitivity, lowered body weight and leptin levels, and increased oxidative metabolism and energy expenditure in mice [207,208] (Figure 2).”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [207] Baek, 2006, Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia, Gastroenterology source
- Not checked yetcites [208] Chrysovergis, 2014, NAG-1/GDF-15 prevents obesity by increasing thermogenesis, lipolysis and oxidative metabolism, International Journal of Obesity source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Hepassocin is secreted predominantly from the liver, but is also expressed in adipose tissue where it is suggested to regulate lipid metabolism [219].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [219] Demchev, 2013, Targeted deletion of fibrinogen like protein 1 reveals a novel role in energy substrate utilization, PloS One source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“GFRAL is exclusively expressed in the human brainstem and is responsible for the metabolic effects of GDF15 on regulating appetite [201,215].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [201] Mullican, 2018, Uniting GDF15 and GFRAL: therapeutic opportunities in obesity and beyond, Trends in Endocrinology and Metabolism source
- Not checked yetcites [215] Hsu, 2017, Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15, Nature source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Conversely, administration of GDF15 to wild-type mice produced responses similar to those in transgenic mice; however, these mice exhibited consistent reduction in food intake [201,213].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [201] Mullican, 2018, Uniting GDF15 and GFRAL: therapeutic opportunities in obesity and beyond, Trends in Endocrinology and Metabolism source
- Not checked yetcites [213] Yang, 2017, GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand, Natura Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“A recent study found that GDF15 induced anorexia through nausea and emesis in mice and musk shrews, respectively [216].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [216] Borner, 2020, GDF15 induces anorexia through nausea and emesis, Cell Metabolism source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Growth differentiation factor 15 (GDF15), also called macrophage inhibitory cytokine-1, is associated with numerous biological processes and diseases including cancer, cardiovascular disease, and obesity [[199], [200], [201], [202]].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [199] Bauskin, 2006, Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer, Cancer Research source
- Not checked yetcites [200] Breit, 2011, The TGF-β superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism, Growth Factors source
- Not checked yetcites [201] Mullican, 2018, Uniting GDF15 and GFRAL: therapeutic opportunities in obesity and beyond, Trends in Endocrinology and Metabolism source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“GDF15 belongs to the TGF-β superfamily and is upregulated by several inflammatory or stress-related proteins, including interleukin (IL)-1β, IL-2, and tumor necrosis factor (TNF) alpha.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Physiological levels of circulating GDF15 are low in healthy humans but increase in disease states and during pregnancy [203] (Table 1).”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [203] Li, 2000, Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression, Journal of Biological Chemistry source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Two studies found that GDF15 transgenic mice were protected against obesity and had increased insulin sensitivity and energy expenditure without any changes in food consumption compared to control mice [207,208].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [207] Baek, 2006, Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia, Gastroenterology source
- Not checked yetcites [208] Chrysovergis, 2014, NAG-1/GDF-15 prevents obesity by increasing thermogenesis, lipolysis and oxidative metabolism, International Journal of Obesity source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“While GDF15 is not highly expressed in the human liver under basal conditions, it is highly expressed in the liver, adipose, and intestine in mice [[204], [205], [206]].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [204] Hsiao, 2000, Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury, Molecular and Cellular Biology source
- Not checked yetcites [205] Baek, 2019, Growth differentiation factor 15 (GDF15): a survival protein with therapeutic potential in metabolic diseases, Pharmacology & Therapeutics source
- Not checked yetcites [206] Lockhart, 2020, GDF15: a hormone conveying somatic distress to the brain, Endocrine Reviews source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Overexpression of FST in mice resulted in insulin resistance in WAT, increased hepatic glucose production, and impaired whole-body glucose tolerance, consistent with higher expression in patients with type 2 diabetes [77,196].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [77] Gonzalez-Gil, 2020, The role of exercise in the interplay between myokines, hepatokines, osteokines, adipokines, and modulation of inflammation for energy substrate redistribution and fat mass loss: a review, Nutrients source
- Not checked yetcites [196] Tao, 2018, Inactivating hepatic follistatin alleviates hyperglycemia, Natura Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“LECT2-deficient mice exhibited increased glucose tolerance and insulin sensitivity [239].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [239] Lan, 2014, LECT2 functions as a hepatokine that links obesity to skeletal muscle insulin resistance, Diabetes source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“While IGF2 functions predominantly in early embryogenesis [226]”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [226] Baker, 1993, Role of insulin-like growth factors in embryonic and postnatal growth, Cell source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“LCN13 in particular is secreted from multiple tissues including the liver to regulate glucose homeostasis and improve insulin sensitivity [254].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [254] Zhou, 2013, Lipocalin 13 regulation of glucose and lipid metabolism in obesity, Vitamins & Hormones source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Administration of recombinant hepassocin or hepatic overexpression of hepassocin in mice induces insulin resistance in the liver and skeletal muscle, while loss of hepassocin improves high-fat diet-induced insulin resistance in wild-type and ob/ob mice [217] (Figure 3).”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [217] Wu, 2016, A novel hepatokine, HFREP1, plays a crucial role in the development of insulin resistance and type 2 diabetes, Diabetologia source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Decreased expression of LECT2 is observed during tissue inflammation, fibrosis, or pathology, suggesting that LECT2 functions positively under normal conditions.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“These mice also exhibited increased insulin-stimulated AKT phosphorylation in skeletal muscle but not in the liver or adipose tissue, suggesting that loss of LECT2 selectively improves insulin sensitivity in skeletal muscle [239].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [239] Lan, 2014, LECT2 functions as a hepatokine that links obesity to skeletal muscle insulin resistance, Diabetes source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“For example, mice that were fed high-fat diets or exercised had increased or decreased serum and hepatic levels of LECT2, respectively [239].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [239] Lan, 2014, LECT2 functions as a hepatokine that links obesity to skeletal muscle insulin resistance, Diabetes source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Lipocalin (LCN) proteins are secreted proteins that bind small hydrophobic ligands through their conical β barrels [252,253].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Insulin-like growth factors (IGFs) are structurally and functionally related to insulin and play an important role in enhancing insulin sensitivity [222].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [222] Moses, 1996, Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes, Diabetes source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“IGF1 is secreted into the circulation by the liver in response to growth hormone stimulation [227].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [227] Van Wyk, 1999, Insulin-like growth factors and skeletal growth: possibilities for therapeutic interventions, Journal of Clinical Endocrinology & Metabolism source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“IGFs are regulated by a family of IGF-binding proteins (IGFBP) that can bind IGFs with equal or greater affinity than IGF1R [224,225].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [224] Rajkumar, 1996, Impaired glucose homeostasis in insulin-like growth factor binding protein-1 transgenic mice, Journal of Clinical Investigation source
- Not checked yetcites [225] Jones, 1995, Insulin-like growth factors and their binding proteins: biological actions∗, Endocrine Reviews
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“There is evidence that low plasma levels of IGF1 predict the development of type 2 diabetes and correlate with insulin resistance and increased risk of metabolic syndrome and cardiovascular disease [[231], [232], [233]] (Table 1).”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [231] Sandhu, 2002, Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study, The Lancet source
- Not checked yetcites [232] Succurro, 2009, Low plasma insulin-like growth factor-1 levels are associated with reduced insulin sensitivity and increased insulin secretion in nondiabetic subjects, Nutrition, Metabolism, and Cardiovascular Diseases source
- Not checked yetcites [233] Juul, 2002, Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study, Circulation source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“LECT2 functions in liver regeneration, immune modulation, bone growth, neural development, glucose metabolism, metabolic syndrome, and cancer [[241], [242], [243], [244], [245], [246]].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [241] Segawa, 2001, Possible changes in expression of chemotaxin LECT2 mRNA in mouse liver after concanavalin A-induced hepatic injury, Biological and Pharmaceutical Bulletin source
- Not checked yetcites [242] Yamagoe, 1996, Purification and primary amino acid sequence of a novel neutrophil chemotactic factor LECT2, Immunology Letters source
- Not checked yetcites [243] Ovejero, 2004, Identification of the leukocyte cell-derived chemotaxin 2 as a direct target gene of beta-catenin in the liver, Hepatology source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Administration of IGF1 in humans results in decreased blood glucose levels and improved insulin sensitivity in those with and without type 2 diabetes [[234], [235], [236]].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [234] Laron, 1995, Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome) before and during insulin-like growth factor-I treatment, Metabolism source
- Not checked yetcites [235] Laron, 1999, The essential role of IGF-I: lessons from the long-term study and treatment of children and adults with Laron syndrome, Journal of Clinical Endocrinology & Metabolism source
- Not checked yetcites [236] Hong, 2017, Central IGF1 improves glucose tolerance and insulin sensitivity in mice, Nutrition & Diabetes source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“IGFBP1 is elevated in patients with type 2 diabetes and has been shown to counteract the hypoglycemic effect of insulin through inhibition of IGF1 [224].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [224] Rajkumar, 1996, Impaired glucose homeostasis in insulin-like growth factor binding protein-1 transgenic mice, Journal of Clinical Investigation source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“LECT2-deficient mice showed improved insulin sensitivity in skeletal muscle, while administration of recombinant LECT2 in mice led to impaired insulin signaling and induced insulin resistance in skeletal muscle [239] (Figure 3).”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [239] Lan, 2014, LECT2 functions as a hepatokine that links obesity to skeletal muscle insulin resistance, Diabetes source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“LECT2 alters insulin signaling through the JNK pathway in myocytes, and the expression of LECT2 in the liver is negatively regulated by the energy-depletion sensor AMPK [239,248,249].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [239] Lan, 2014, LECT2 functions as a hepatokine that links obesity to skeletal muscle insulin resistance, Diabetes source
- Not checked yetcites [248] Hwang, 2015, LECT2 induces atherosclerotic inflammatory reaction via CD209 receptor-mediated JNK phosphorylation in human endothelial cells, Metabolism source
- Not checked yetcites [249] Hwang, 2015, A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression, Biochemical Pharmacology source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“it is well established that LCN13 regulates glucose metabolism in adipocytes and hepatocytes by enhancing insulin signaling, insulin-stimulated glucose uptake, and insulin suppression of glucose production [254,258].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [254] Zhou, 2013, Lipocalin 13 regulation of glucose and lipid metabolism in obesity, Vitamins & Hormones source
- Not checked yetcites [258] Cho, 2011, Lipocalin-13 regulates glucose metabolism by both insulin-dependent and insulin-independent mechanisms, Molecular and Cellular Biology source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Liver injury in mice enhances the expression of hepassocin in adipose tissues, suggesting crosstalk between the liver and adipose tissue, although its role in obesity remains obscure [219].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [219] Demchev, 2013, Targeted deletion of fibrinogen like protein 1 reveals a novel role in energy substrate utilization, PloS One source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Altogether, it is clear that IGF1 plays an important role in maintaining insulin sensitivity; however, the full mechanism by which it does so has not been completely resolved.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The two main IGFs, IGF1 and IGF2, bind the IGF1 receptor (IGF1R), which elicits phosphorylation of intracellular adaptor proteins and activation of MAPK and PI3K/AKT signaling pathways [223].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [223] Menu, 2004, Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model, British Journal of Cancer source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Interestingly, tissues normally lacking LECT2 exhibit increased expression of LECT2 in disease settings, indicating that improper upregulation of LECT2 may contribute to pathological conditions [246,247].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [246] Slowik, 2017, Leukocyte cell-derived chemotaxin-2: it's role in pathophysiology and future in clinical medicine, Clin Transl Sci source
- Not checked yetcites [247] Nagai, 1998, Systemic expression of a newly recognized protein, LECT2, in the human body, Pathology International source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“LECT2 is expressed in the liver, adipose tissue, neurons, and white blood cells and is often found in the circulation.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Interestingly, there is a positive relationship between circulating LECT2 levels, BMI, and insulin resistance in humans [239] (Table 1).”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [239] Lan, 2014, LECT2 functions as a hepatokine that links obesity to skeletal muscle insulin resistance, Diabetes source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“IGFs promotes cell growth, proliferation, differentiation, and survival in an endocrine, paracrine, and autocrine fashion.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Expression and secretion of LCN13 in mice vary in response to changes in metabolic states, suggesting a role for this hepatokine in nutrient sensing and regulation [254].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [254] Zhou, 2013, Lipocalin 13 regulation of glucose and lipid metabolism in obesity, Vitamins & Hormones source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Administration of a long-lasting SMOC1-Fc fusion protein improved glycemic control, cholesterol, and NAFLD activity scores in lean and obese mice up to 4 weeks following the final administration of SMOC1-Fc [266].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [266] Montgomery, 2020, SMOC1 is a glucose-responsive hepatokine and therapeutic target for glycemic control, Science Translational Medicine source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Selenoprotein P (SeP) is a glycoprotein that is secreted predominantly from the liver and is upregulated by selenium and glucose supplies but downregulated by insulin and adiponectin [260,261].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [260] Misu, 2010, A liver-derived secretory protein, selenoprotein P, causes insulin resistance, Cell Metabolism source
- Not checked yetcites [261] Misu, 2012, Inverse correlation between serum levels of selenoprotein P and adiponectin in patients with type 2 diabetes, PloS One source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Mice overexpressing LCN13 are resistant to high-fat diet-induced hepatic steatosis and hyperlipidemia [259].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [259] Sheng, 2011, Lipocalin 13 protein protects against hepatic steatosis by both inhibiting lipogenesis and stimulating fatty acid β-oxidation, Journal of Biological Chemistry source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The liver responds to energy influx and demand by secreting hepatokines that act on various tissues to facilitate energy utilization or storage.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Conclusion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These hepatokines can act in isolation or in conjunction with other factors to coordinate systemic metabolic processes.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Conclusion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Tsukushi (TSK) is an inducible hepatokine that regulates energy expenditure and is strongly associated with NAFLD, NASH, and obesity [269,270].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [269] Mouchiroud, 2019, The hepatokine Tsukushi is released in response to NAFLD and impacts cholesterol homeostasis, JCI Insight source
- Not checked yetcites [270] Xiong, 2019, Mapping the molecular signatures of diet-induced NASH and its regulation by the hepatokine Tsukushi, Mol Metab source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Interestingly, SMOC1 has no effect on food intake, body weight, or energy expenditure.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“TSK-deficient mice were resistant to diet-induced obesity, insulin resistance, and hepatic steatosis as a result of enhanced sympathetic activation and brown fat thermogenesis [271].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [271] Wang, 2019, The hepatokine Tsukushi gates energy expenditure via brown fat sympathetic innervation, Nat Metab source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“LCN13 likely regulates lipid metabolism by downregulating the expression of key liver lipogenic genes including ChREBP and PPARγ and upregulating hepatic expression of carnitine palmitoyltransferase-1α (CPT1α) to decrease lipogenesis and increase fatty acid β-oxidation [259].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [259] Sheng, 2011, Lipocalin 13 protein protects against hepatic steatosis by both inhibiting lipogenesis and stimulating fatty acid β-oxidation, Journal of Biological Chemistry source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“SMOC1 is widely expressed in multiple tissues and generally localized at the basement membrane of cells.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The discrepancies in findings between groups may have been due to the differences in TSK knockout mouse models that were generated and/or variations in diet composition that were used.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Plasma levels of SMOC1 decrease in patients with insulin-resistance compared with insulin-sensitive individuals and correlate with hepatic and peripheral insulin sensitivity (Table 1).”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“SPARC-related modular calcium-binding protein-1 (SMOC1) is a hepatokine recently identified to improve glucose homeostasis in rodents [266].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [266] Montgomery, 2020, SMOC1 is a glucose-responsive hepatokine and therapeutic target for glycemic control, Science Translational Medicine source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Beneficial hepatokines that improve metabolic dysfunction include activin-E, ANGPTL4, ANGPTL6, FGF21, GDF15, IGF-1, LCN13, SMOC1, and TSK.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Conclusion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Their concentrations and effects are altered in response to metabolic stressors, and dysregulation in their signaling can result in pathologies including obesity, type 2 diabetes, and NAFLD.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Conclusion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The regulation of whole-body energy homeostasis by the liver is a complex process that involves tissue crosstalk through the production of hepatokines and changes in hepatic metabolism in response to metabolic cues and substrates.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Conclusion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
In the paper
“whereas SeP knockout mice showed improved glucose tolerance and insulin resistance [260].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [260] Misu, 2010, A liver-derived secretory protein, selenoprotein P, causes insulin resistance, Cell Metabolism source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“SeP is associated with insulin resistance and increased serum triglyceride, and patients with NAFLD, obesity, and type 2 diabetes have high circulating levels of SeP [260,263,264] (Table 1).”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [260] Misu, 2010, A liver-derived secretory protein, selenoprotein P, causes insulin resistance, Cell Metabolism source
- Not checked yetcites [263] Misu, 2019, Identification of hepatokines involved in pathology of type 2 diabetes and obesity, Endocrine Journal source
- Not checked yetcites [264] Yang, 2011, Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis, Journal of Clinical Endocrinology & Metabolism source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These hepatokines improve whole organism energy homeostasis by accomplishing one or more of the following (1) increasing energy expenditure through brown and beige adipocyte activation, (2) increasing insulin sensitivity, (3) increasing glucose uptake, (4) decreasing plasma triglyceride concentrations and regulating cholesterol homeostasis, (5) decreasing body weight, and (6) lowering food intake.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Conclusion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Chronic decreased levels of detrimental hepatokines, including ANGPTL3, ANGPTL8, fetuin-A, hepassocin, LECT-2, and SeP aid in maintaining insulin sensitivity, lipid homeostasis, and healthy body weight by decreasing systemic inflammation and insulin resistance.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Conclusion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Mice lacking TSK exhibit elevated core body temperatures and are unable to adequately suppress energy expenditure during starvation, leading to greater body weight loss.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Loss of hepatic SMOC1 impairs glycemic control in lean mice, whereas acute SMOC1 administration and chronic hepatic SMOC1 overexpression improves glycemic control in lean and obese mice.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“SMOC1 is known to regulate cell matrix interactions by binding to cell surface receptors, including laminins, C-reactive protein, and tenascin-C [266,268].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [266] Montgomery, 2020, SMOC1 is a glucose-responsive hepatokine and therapeutic target for glycemic control, Science Translational Medicine source
- Not checked yetcites [268] Wang, 2018, SMOC1 silencing suppresses the angiotensin II-induced myocardial fibrosis of mouse myocardial fibroblasts via affecting the BMP2/Smad pathway, Oncol Lett
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“However, SMOC1 is highly expressed and secreted by the liver and regulates glucose homeostasis [266].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [266] Montgomery, 2020, SMOC1 is a glucose-responsive hepatokine and therapeutic target for glycemic control, Science Translational Medicine source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“SeP expression increased in mice in response to ER stress and JNK activation, while activation of AMPK protected against SeP production (Figure 3).”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“TSK was recently identified as an atypical member of the small leucine-rich proteoglycan family that regulates developmental processes in various organisms [[269], [270], [271]].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [269] Mouchiroud, 2019, The hepatokine Tsukushi is released in response to NAFLD and impacts cholesterol homeostasis, JCI Insight source
- Not checked yetcites [270] Xiong, 2019, Mapping the molecular signatures of diet-induced NASH and its regulation by the hepatokine Tsukushi, Mol Metab source
- Not checked yetcites [271] Wang, 2019, The hepatokine Tsukushi gates energy expenditure via brown fat sympathetic innervation, Nat Metab source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“SMOC1 belongs to a family of matricellular proteins including secreted protein acidic and rich in cysteine (SPARC), SMOC2, and testican-1 [267].”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [267] Awwad, 2015, Role of secreted modular calcium-binding protein 1 (SMOC1) in transforming growth factor β signalling and angiogenesis, Cardiovascular Research source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Wild-type mice treated with SeP exhibited whole-body glucose intolerance and insulin resistance [260]”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
What the sources say
- Not checked yetcites [260] Misu, 2010, A liver-derived secretory protein, selenoprotein P, causes insulin resistance, Cell Metabolism source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hepatic and plasma levels of this hepatokine are strongly stimulated by stimuli that augment thermogenesis and energy expenditure (including adrenergic agonists and cold exposure) [78,88,89].”
From Adipokines, Myokines, and Hepatokines: Crosstalk and Metabolic Repercussions (2021) · cites this paper as [88]
In the citing paper
“Angptl8 is a hepatokine related to the reset of diurnal rhythms of hepatic clock, and metabolic genes in mice [88,90,91].”
From Adipokines, Myokines, and Hepatokines: Crosstalk and Metabolic Repercussions (2021) · cites this paper as [88]
In the citing paper
“The main hepatokines related to insulin resistance, a fundamental factor in the development of DM2 and obesity, are fetuin-A, hepassocin, LECT2, and selenoprotein.”
From Adipokines, Myokines, and Hepatokines: Crosstalk and Metabolic Repercussions (2021) · cites this paper as [88]
In the citing paper
“Physiological circulating levels of FGF21 are produced primarily by the liver in response to homeostatic imbalance, perhaps partly to protect the liver itself from metabolic or cellular stress3,104.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Hepatokines and metabolism: Deciphering communication from the liver > Conclusion
“Beneficial hepatokines that improve metabolic dysfunction include activin-E, ANGPTL4, ANGPTL6, FGF21, GDF15, IGF-1, LCN13, SMOC1, and TSK.”
§ Hepatokines and metabolism: Deciphering communication from the liver > Introduction > The liver and hepatokines
“TSK-deficient mice were resistant to diet-induced obesity, insulin resistance, and hepatic steatosis as a result of enhanced sympathetic activation and brown fat thermogenesis [271].”
Citations
Cites
Items 201–276 of 276
Berti, L., Irmler, M., Zdichavsky, M., Meile, T., Böhm, A., Stefan, N., Fritsche, A., Beckers, J., Königsrainer, A., Häring, H.-U., et al. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.04.002 · Cited by 73
Cinkajzlová, A., Mráz, M., Lacinová, Z., Kloučková, J., Kaválková, P., Kratochvílová, H., Trachta, P., Křížová, J., Haluzíková, D., Škrha, J., et al. (2018) · Nutrition & Diabetes · doi:10.1038/s41387-018-0032-2 · Cited by 73
Hwang, H.-J., Jung, T. W., Kim, B.-H., Hong, H. C., Seo, J. A., Kim, S. G., Kim, N. H., Choi, K. M., Choi, D. S., Baik, S. H., et al. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.08.098 · Cited by 72
Hansen, J., Rinnov, A., Krogh‐Madsen, R., Fischer, C. P., Andreasen, A. S., Berg, R. M. G., Møller, K., Pedersen, B. K., & Plomgaard, P. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2415 · Cited by 71
Differential distribution of follistatin isoforms: application of a new FS315-specific immunoassay
Schneyer, A. L., Wang, Q., Sidis, Y., & Sluss, P. M. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0162 · Cited by 71
Tjeerdema, N., Georgiadi, A., Jonker, J. T., van Glabbeek, M., Dehnavi, R. A., Tamsma, J. T., Smit, J. W. A., Kersten, S., & Rensen, P. C. N. (2014) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2014-000034 · Cited by 71
Implication of hepatokines in metabolic disorders and cardiovascular diseases
Jung, T. W., Yoo, H. J., & Choi, K. M. (2016) · BBA Clinical · doi:10.1016/j.bbacli.2016.03.002 · Cited by 71
The hepatokine Tsukushi gates energy expenditure via brown fat sympathetic innervation
Wang, Q., Sharma, V. P., Shen, H., Xiao, Y., Zhu, Q., Xiong, X., Guo, L., Jiang, L., Ohta, K., Li, S., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-018-0020-9 · Cited by 71
Shimamura, M., Matsuda, M., Ando, Y., Koishi, R., Yasumo, H., Furukawa, H., & Shimomura, I. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.024 · Cited by 67
Takata, H., Ikeda, Y., Suehiro, T., Ishibashi, A., Inoue, M., Kumon, Y., & Terada, Y. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.no950 · Cited by 66
Yilmaz, Y. N., Yönal, O., Kurt, R., Arı, F., Oral, A. Y., Çelikel, Ç., KORKMAZ, Ş., Ulukaya, E., Ozdogan, O. C., İmeryüz, N., et al. (2010) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2010.010169 · Cited by 66
Andersen, B., Straarup, E. M., Heppner, K. M., Takahashi, D. L., Raffaele, V., Dissen, G. A., Lewandowski, K., Bödvarsdottir, T. B., Raun, K., Grove, K. L., et al. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0080-7 · Cited by 66
Expression of angiopoietin-like 4 in human gastric cancer: ANGPTL4 promotes venous invasion
Nakayama (2010) · Oncology Reports · doi:10.3892/or_00000897 · Cited by 64
Yilmaz, Y. N., Ulukaya, E., Atuğ, Ö., & Dolar, E. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32832b77ae · Cited by 63
Investigating the Role of Myeloperoxidase and Angiopoietin-like Protein 6 in Obesity and Diabetes
Qaddoumi, M. G., Alanbaei, M., Hammad, M. M., Khairi, I. A., Cherian, P., Channanath, A. M., Thanaraj, T. A., Al‐Mulla, F., Abu‐Farha, M., & Abubaker, J. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-63149-7 · Cited by 63
SMOC1 is a glucose-responsive hepatokine and therapeutic target for glycemic control
Montgomery, M. K., Bayliss, J., Devereux, C., Bezawork-Geleta, A., Roberts, D., Huang, C., Schittenhelm, R. B., Ryan, A., Townley, S. L., Selth, L. A., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz8048 · Cited by 63
Circulating follistatin in relation to energy metabolism
Hansen, J. S., & Plomgaard, P. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.06.002 · Cited by 62
Hwang, H.-J., Jung, T. W., Hong, H. C., Seo, J. A., Kim, S. G., Kim, N. H., Choi, K. M., Choi, D. S., Baik, S. H., & Yoo, H. J. (2015) · Metabolism · doi:10.1016/j.metabol.2015.06.001 · Cited by 60
Matsusue, K., Miyoshi, A., Yamano, S., & Gonzalez, F. J. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.05.005 · Cited by 60
Choi, K. M., Han, K. A., Ahn, H. J., Lee, S. Y., Hwang, S. Y., Kim, B. C., Hong, H. C., Choi, H. Y., Yang, S. J., Yoo, H. J., et al. (2012) · Clinical Endocrinology · doi:10.1111/cen.12076 · Cited by 60
The Lipoprotein Lipase Inhibitor ANGPTL3 Is Negatively Regulated by Thyroid Hormone
Fugier, C., Tousaint, J.-J., Prieur, X., Plateroti, M., Samarut, J., & Delerive, P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512554200 · Cited by 60
Romeo, S., Yin, W., Kozlitina, J., Pennacchio, L. A., Boerwinkle, E., Hobbs, H. H., & Cohen, J. C. (2008) · Journal of Clinical Investigation · doi:10.1172/jci37118 · Cited by 58
The hepatokine Tsukushi is released in response to NAFLD and impacts cholesterol homeostasis
Mouchiroud, M., Camiré, É., Aldow, M., Caron, A., Jubinville, É., Turcotte, L., Kaci, I., Beaulieu, M.-J., Roy, C., Labbé, S. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.129492 · Cited by 57
Pérez‐Martí, A., Garcia‐Guasch, M., Tresserra‐Rimbau, A., Carrilho‐Do‐Rosário, A., Estruch, R., Salas‐Salvadó, J., Martínez‐González, M. Á., Lamuela‐Raventós, R., Marrero, P. F., Haro, D., et al. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201600725 · Cited by 56
Follistatin and follistatin like-3 differentially regulate adiposity and glucose homeostasis
Brown, M. L., Bonomi, L., Ungerleider, N., Zina, J., Kimura, F., Mukherjee, A., Sidis, Y., & Schneyer, A. (2011) · Obesity · doi:10.1038/oby.2011.97 · Cited by 55
Morinaga, J., Zhao, J., Endo, M., Kadomatsu, T., Miyata, K., Sugizaki, T., Okadome, Y., Tian, Z., Horiguchi, H., Miyashita, K., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193731 · Cited by 55
cDNA cloning and expression of human activin βE subunit
Hashimoto, O., Tsuchida, K., Ushiro, Y., Hosoi, Y., Hoshi, N., Sugino, H., & Hasegawa, Y. (2002) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(02)00157-0 · Cited by 54
Serum levels of angiopoietin-related growth factor are increased in metabolic syndrome
Namkung, J., Koh, S. B., Kong, I. D., Choi, J.-W., & Yeh, B.-I. (2010) · Metabolism · doi:10.1016/j.metabol.2010.05.013 · Cited by 54
Dang, F., Wu, R., Wang, P., Wu, Y., Azam, M. S., Xu, Q., Chen, Y., & Liu, Y. (2016) · Scientific Reports · doi:10.1038/srep36926 · Cited by 54
Singh, R., Braga, M., Reddy, S. T., Lee, S.-J., Parveen, M., Grijalva, V., Vergnes, L., & Pervin, S. (2017) · Endocrinology · doi:10.1210/en.2016-1607 · Cited by 54
Central IGF1 improves glucose tolerance and insulin sensitivity in mice
Hong, H., Cui, Z.-Z., Zhu, L., Fu, S.-P., Rossi, M., Cui, Y.-H., & Zhu, B.-M. (2017) · Nutrition & Diabetes · doi:10.1038/s41387-017-0002-0 · Cited by 54
Role of exercise-induced hepatokines in metabolic disorders
Ennequin, G., Sirvent, P., & Whitham, M. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00433.2018 · Cited by 54
Insulin-like growth factors and skeletal growth: possibilities for therapeutic interventions
Van Wyk, J. J., & Smith, E. P. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.12.6201 · Cited by 53
LECT2 promotes inflammation and insulin resistance in adipocytes via P38 pathways
Jung, T. W., Chung, Y. H., Kim, H.-C., Abd El-Aty, A. M., & Jeong, J. H. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-17-0267 · Cited by 53
Gao, M., Zhan, Y.-Q., Yu, M., Ge, C.-H., Li, C.-Y., Zhang, J.-H., Wang, X.-H., Ge, Z.-Q., & Yang, X.-M. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.04.013 · Cited by 52
Sugiyama, M., Kikuchi, A., Misu, H., Igawa, H., Ashihara, M., Kushima, Y., Honda, K., Suzuki, Y., Kawabe, Y., Kaneko, S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194798 · Cited by 52
Fetuin-A in Metabolic syndrome: A systematic review and meta-analysis
Pan, X., Wen, S. W., Bestman, P. L., Kaminga, A. C., Acheampong, K., & Liu, A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229776 · Cited by 52
Serum levels of angiopoietin-related growth factor in diabetes mellitus and chronic hemodialysis
Ebert, T., Bachmann, A., Lössner, U., Kratzsch, J., Blüher, M., Stümvoll, M., & Faßhauer, M. (2009) · Metabolism · doi:10.1016/j.metabol.2008.11.016 · Cited by 51
Ozaki, Y., Saito, K., Nakazawa, K., Konishi, M., Itoh, N., Hakuno, F., Takahashi, S.-I., Kato, H., & Takenaka, A. (2015) · British Journal Of Nutrition · doi:10.1017/s0007114515002846 · Cited by 51
Circulating Betatrophin Levels Are Increased in Anorexia and Decreased in Morbidly Obese Women
Barja-Fernández, S., Folgueira, C., Seoane, L. M., Casanueva, F. F., Diéguez, C., Castelao, C., Agüera, Z., Baños, R., Botella, C., de la Torre, R., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1595 · Cited by 50
Systemic expression of a newly recognized protein, LECT2, in the human body
Nagal, H., Hamada, T., Uchida, T., Yamagoe, S., & Suzuki, K. (1998) · Pathology International · doi:10.1111/j.1440-1827.1998.tb03855.x · Cited by 50
Flippo, K. H., Jensen-Cody, S. O., Claflin, K. E., & Potthoff, M. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-76593-2 · Cited by 49
Self-citationClinical and therapeutic implications of follistatin in solid tumours
SHI, L., RESAUL, J., OWEN, S., YE, L., & JIANG, W. G. (2016) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20005 · Cited by 47
Smati, S., Régnier, M., Fougeray, T., Polizzi, A., Fougerat, A., Lasserre, F., Lukowicz, C., Tramunt, B., Guillaume, M., Burnol, A.-F., et al. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.05.005 · Cited by 47
Role of hepatokines in non-alcoholic fatty liver disease
Ke, Y., Xu, C., Lin, J., & Li, Y. (2019) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2019-0029 · Cited by 46
Sheng, L., Cho, K. W., Zhou, Y., Shen, H., & Rui, L. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.256677 · Cited by 45
Kitazawa, M., Ohizumi, Y., Oike, Y., Hishinuma, T., & Hashimoto, S. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.127530 · Cited by 44
Leukocyte cell-derived chemotaxin-2: it's role in pathophysiology and future in clinical medicine
Slowik, V, & Apte, U. (2017) · Clinical and Translational Science · doi:10.1111/cts.12469 · Cited by 44
Barja-Fernández, S., Moreno‐Navarrete, J. M., Folgueira, C., Xifra, G., Sabater, M., Castelao, C., Fernø, J., Leis, R., Diéguez, C., Casanueva, F. F., et al. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201800060 · Cited by 43
Cho, K. W., Zhou, Y., Sheng, L., & Rui, L. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.00459-10 · Cited by 42
Pramfalk, C., Parini, P., Gustafsson, U. O., Sahlin, S., & Eriksson, M. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02305.x · Cited by 40
Direct Inhibitory Effects of Pioglitazone on Hepatic Fetuin-A Expression
Ochi, A., Mori, K., Emoto, M., Nakatani, S., Morioka, T., Motoyama, K., Fukumoto, S., Imanishi, Y., Koyama, H., Ishimura, E., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088704 · Cited by 40
Overcoming Insulin Insufficiency by Forced Follistatin Expression in β -cells of db/db Mice
Zhao, C., Qiao, C., Tang, R., Jiang, J., Li, J., Martin, C. B., Bulaklak, K., Li, J., Wang, D. W., & Xiao, X. (2015) · Molecular Therapy · doi:10.1038/mt.2015.29 · Cited by 37
Regulation of the expression of follistatin in rat hepatocytes
Zhang, Y.-Q., Kanzaki, M., Shibata, H., & Kojima, I. (1997) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(97)00085-7 · Cited by 36
Control of diabetic hyperglycaemia and insulin resistance through TSC22D4
Ekim Üstünel, B., Friedrich, K., Maida, A., Wang, X., Krones-Herzig, A., Seibert, O., Sommerfeld, A., Jones, A., Sijmonsma, T. P., Sticht, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms13267 · Cited by 36
Willis, S. A., Sargeant, J. A., Yates, T., Takamura, T., Takayama, H., Gupta, V., Brittain, E., Crawford, J., Parry, S. A., Thackray, A. E., et al. (2020) · The Journal of Nutrition · doi:10.1093/jn/nxz333 · Cited by 34
Identification of hepatokines involved in pathology of type 2 diabetes and obesity
Misu, H. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej19-0255 · Cited by 32
Tuhan, H., Abacı, A., Anık, A., Çatlı, G., Küme, T., Çalan, Ö. G., Acar, S., & Böber, E. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.02.008 · Cited by 31
Can targeting ANGPTL proteins improve glucose tolerance?
Davies, B. S. J. (2018) · Diabetologia · doi:10.1007/s00125-018-4604-4 · Cited by 30
Lipocalin 13 regulation of glucose and lipid metabolism in obesity
Zhou, Y., & Rui, L. (2013) · Vitamins & Hormones · doi:10.1016/b978-0-12-407766-9.00015-8 · Cited by 28
Wang, R., Yuan, J., Zhang, C., Wang, L., Liu, Y., Song, L., Zhong, W., Chen, X., & Dong, J. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00451 · Cited by 27
Circulating Angptl3 and Angptl8 Are Increased in Patients with Hypothyroidism
Yang, L., Yin, R., Wang, Z., Wang, X., Zhang, Y., & Zhao, D. (2019) · BioMed Research International · doi:10.1155/2019/3814687 · Cited by 27
The implication of hepatokines in metabolic syndrome
Esfahani, M., Baranchi, M., & Goodarzi, M. T. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.06.027 · Cited by 24
Discovery of a role of the novel hepatokine, hepassocin, in obesity
Huang, R., Li, C., Du, Y., Cheng, K., Lin, C., Hu, C., Wu, J. S., Chang, C., Wu, H., & Ou, H. (2020) · BioFactors · doi:10.1002/biof.1574 · Cited by 24
Mouchiroud, M., Camiré, É., Aldow, M., Caron, A., Jubinville, É., Turcotte, L., Kaci, I., Beaulieu, M.-J., Roy, C., Labbé, S. M., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.014 · Cited by 24
SEGAWA, Y., ITOKAZU, Y., INOUE, N., SAITO, T., & SUZUKI, K. (2001) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.24.425 · Cited by 22
Lee, K.-Y., Lee, W., Jung, S.-H., Park, J., Sim, H., Choi, Y., Park, Y., Chung, Y., & Lee, B. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.05.011 · Cited by 20
Wang, Y., & Wu, X. (2018) · Oncology Letters · doi:10.3892/ol.2018.8989 · Cited by 19
Angiopoietin-like 4 promotes melanoma cell invasion and survival through aldolase A
Sun, Y., Long, J., & Zhou, Y. (2014) · Oncology Letters · doi:10.3892/ol.2014.2071 · Cited by 18
Telgenkamp, I., Kusters, Y. H. A. M., Schalkwijk, C. G., Houben, A. J. H. M., Kooi, M. E., Lindeboom, L., Bons, J. A. P., Schaper, N. C., Joris, P. J., Plat, J., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02378 · Cited by 18
Koshimizu, Y., & Ohtomi, M. (2009) · Brain Research · doi:10.1016/j.brainres.2009.11.010 · Cited by 17
Hyperinsulinaemia: does it tip the balance toward intrahepatic fat accumulation?
Hodson, L., & Karpe, F. (2019) · Endocrine Connections · doi:10.1530/ec-19-0350 · Cited by 16
Fan, K., Wu, H., Wei, J., Chuang, L., Hsu, C., Yen, I., Lin, C., Lin, M., Shih, S., Wang, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa103 · Cited by 16
炭水化物摂取を抑制する腹内側視床下部におけるグルタミン酸作動性ニューロンへのFGF21シグナル【JST・京大機械翻訳】
Sharon, O., Kyle, H. F., Kristin, E. C., Yavuz, Y., Sarah, A. S., Grant, C., Yuriy, M. U., Atasoy, D., Matthew, P., & Matthew, J. P. (2020) · Cell Metabolism · Cited by 15
Hurt‐Camejo, E. (2020) · Journal of Lipid Research · doi:10.1194/jlr.c120000650 · Cited by 11
Ozaki, Y., Saito, K., Nakazawa, K., Konishi, M., Itoh, N., Hakuno, F., Takahashi, S., Kato, H., & Takenaka, A. (2015) · British Journal Of Nutrition · doi:10.1017/s0007114515003955 · Cited by 4
Research works printed but not linked: 1
- Patrick Auberger, 1989, Jean olivier contreres, gilles pages, ginette le cam, bernard rossi, alphonse le cam, vol. 58
Cited by
Sorted by citations
Flippo, K. H., & Potthoff, M. J. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00354-2 · Cited by 311
Self-citationThe role of hepatokines in NAFLD
Stefan, N., Schick, F., Birkenfeld, A. L., Häring, H., & White, M. F. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.006 · Cited by 288
Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer
Kasprzak, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126434 · Cited by 248
Sandireddy, R., Sakthivel, S., Gupta, P., Behari, J., Tripathi, M., & Singh, B. K. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1433857 · Cited by 235
Adipokines, Myokines, and Hepatokines: Crosstalk and Metabolic Repercussions
de Oliveira dos Santos, A. R., de Oliveira Zanuso, B., Miola, V. F. B., Barbalho, S. M., Santos Bueno, P. C., Flato, U. A. P., Detregiachi, C. R. P., Buchaim, D. V., Buchaim, R. L., Tofano, R. J., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052639 · Cited by 189
Metadata
- Authors
- Jensen-Cody, S. O., & Potthoff, M. J.
- Affiliations
- University of Iowa (US)
- Corresponding author
- Potthoff, Matthew J.
- ORCID
- Potthoff, Matthew J.
- Venue
- Molecular Metabolism
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 44
- Pages
- 101138
- ISSN
- 2212-8778 (ISSN-L)
- PMC
- PMC7788242
- OpenAlex
- W3112435365
- Cited by
- 252
- References
- 278
- Citations by year
- 2026: 42 · 2025: 54 · 2024: 58 · 2023: 41 · 2022: 36 · 2021: 21
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecular Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health
- U.S. Department of Veterans Affairs
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- hepatokines, energy homeostasis, inter-organ communication, glucose metabolism, lipid metabolism, insulin resistance, hepatic steatosis, metabolic dysfunction, therapeutic target
- MeSH terms
- Nutrients, Animals, Diabetes Mellitus, Type 2, Fatty Liver, Glucose, Homeostasis, Humans, Insulin Resistance, Liver, Metabolic Diseases, Obesity, Cytokines, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
